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ABSTRACT 
Pulmonary tuberculosis (TB) is an infection and communicable disease caused by Mycobacterium 
tuberculosis. One of the risks to develop active tuberculosis is diabetes mellitus (DM), with two or three 
times higher than TB patients without DM. Several studies have reported that DM was associated with 
poor clinical outcomes characterized by a delay of smear sputum conversion or culture conversion in 
TB patients with DM. However, very limited studies that analyze uncontrolled diabetes by HbA1c level 
with clinical outcome of TB treatment. This study aims to review the correlation between HbA1c levels 
and sputum or culture conversion in TB patients with DM. Pubmed, Web of Science, and Embase 
database were used to search and select the article. We included five studies that met the inclusion 
criteria. Smear conversion rate at two months was lower in TB patients with DM than those without DM. 
Uncontrolled HbA1c levels > 6.5%-7.0% were significantly associated with smear conversion of culture 
conversion for more than two months with a high risk of treatment failure. The positive level of smear 
sputum at 2-3 months or the end of the intensive phase becomes a strong predictor a failure treatment at 
the end of the advanced phase. It can be concluded that HbA1c levels delay the smear sputum or culture 
sputum for more than two months. This review highlights a need for more attention to control HbA1c 
levels in TB patients with DM to achieve a better outcome.  
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INTRODUCTION 
 Pulmonary tuberculosis (pulmonary TB) is 
an infectious disease caused by Mycobacterium 
tuberculosis and still an unresolved problem 
worldwide. About a third of the world's 
population is thought to have a latent infection 
of Mycobacterium tuberculosis, and 95% of 
them were found in developing countries. One 
of the risk factors for tuberculosis is diabetes 
mellitus (DM).1   It was supposed that diabetic 
patients have a dysregulation of the immune 
system that leads to tuberculosis development. 
Diabetic patients have several times fold risk of 
suffering from TB than those without DM.  
Based on the world health organization(WHO), 
Indonesia is estimated as the fifth highest 
country with diabetes in 2025.2 
 Several studies reported that diabetes 
mellitus has negative impacts on 
antituberculosis treatment. DM was 
significantly associated with culture sputum that 
was still positive after six months of treatment 
of antituberculosis. A meta-analysis study by 
Baker et al. showed different sputum culture 
conversion findings after 2-3 months of 
treatment with antituberculosis in TB patients 
with DM. The risk of treatment failure was 1.7 
times higher than those without DM.3 A high 
risk of infection, especially tuberculosis among 
type 2 diabetes mellitus (T2DM) patients, may 
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depend on HbA1c as a glycemic control 
parameter. Some studies including randomized 
trials and observational, have consistently 
shown that good glycemic control could reduce 
the risk of diabetic microvascular complications 
by 10%–25%.4,5 However, the effect of HbA1c 
level on infections has not been examined in 
randomized trials.6,7 Because of the data from 
some observational studies, it was difficult to 
interpret the data from inconsistent results. 
Furthermore, the HbA1c level usually was 
measured at once in patients with prevalent  
diabetes, making it difficult to understand the 
importance of acute hyperglycemia or 
hyperglycemia for a long time. 8  
 Hemoglobin A1c (HbA1c) is glycated 
hemoglobin and is considered as a mean glucose 
level over the past 90 days.9 The measurement 
level of HbA1c has a strong relationship with the 
prevalence of type 2 diabetes mellitus (T2DM) 
in numerous studies. In T2DM, patients with a 
high level of HbA1c with more than 53mmol/ml 
are associated with an increased risk of active 
pulmonary TB.10 An association between DM 
and time to sputum conversion in TB patients 
has been observed by Alisjahbana et al., who 
stated that the failure of sputum conversion at 
the end of the second month of treatment TB in 
TB patients with DM was higher than those 
without DM. Still, his study did not evaluate 
some factors that affect sputum conversion.11 
Moreover, diabetes mellitus has been reported 
by several studies as the main factor that inhibits 
sputum conversion at the end of the second 
month of TB treatment. The proportion of 
sputum culture conversion at two months after 
the intensive phase of TB treatment in TB with 
T2DM was 17.1% and without DM was 18.3%, 
and it seems to be similar. However, at the end 
of the advanced phase (four months), the 
positive culture was higher in T2DM patients 
(22.2%) compared to patients without T2DM 
(9.6%).11 A study by Wijayanto et al. stated that 
the level of HbA1c more than 8% was associated 
with TB in T2DM patients.12  
 A high level of HbA1c would increase the 
risk failure of sputum smear conversion 2.3 
more significant in TB patients with diabetes. 
Although many studies have reported that 
diabetes was one of the risk factors that impaired  
the outcome of antituberculosis drugs, few 
studies analyze the association between HbA1c 
and sputum smear or sputum culture conversion 
in TB patients with diabetes. However, most of 
the published studies were observational 
studies. These findings remain unclear because 
of the differences in sample type of TB patients, 
methods, time to diagnose DM during TB 
treatment, etc. In this review, we discussed 
whether a high level of HbA1c impaired the 
tuberculosis treatment of TB patients with DM 
in sputum smear or sputum culture conversion 
 
METHODS 
This review aims to determine whether 
uncontrolled HbA1c impaired the TB treatment 
in TB-DM patients compared to TB without DM 
in sputum smear or sputum culture conversion. 
We collected the articles from Pubmed, 
Web of Science, and Embase database published 
in 2015-2020. We used published articles, both 
written in English and Indonesia. The keywords 
to search the articles were: tuberculosis AND 
"diabetes mellitus" AND (HbA1C or "glycemic 
control" AND "sputum smear conversion" or 
"sputum culture conversion" The selected 
articles, including titles and abstracts, will be 
read and screened that matches the purpose of 
this study. 
We used the articles for both retrospective 
and prospective studies. The inclusion criteria in 
this review were: (1) studies both experimental 
design (randomized controlled trial) and 
observational (cohort, cross-sectional, and case-
control) that analyze or discuss HbA1c, (2) 
patients were diagnosed pulmonary TB with 
diabetes as well as HbA1c data and sputum 
results were available, (3) all patients in both 
groups were measured sputum smear or sputum 
culture conversion at 2-3 months or sixth 
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months. We excluded the articles if: (1)animal 
experiments study, (2) reviews, letters, brief 
communication and case report study, (3) 
pulmonary TB patients complicated with 
autoimmune or immunodeficiency diseases 
such as systemic lupus, rheumatoid arthritis 
which need long-term use of steroids, (4) 




Five studies met the inclusion criteria 
from several databases, as shown in table 1.  
 
Table 1. Article Characteristics. 
Author and Year Study Design Number of 
Subjects 
Findings  
Ratnawati et al., 2018 
13 
A prospective cohort study 
of new cases of pulmonary 
TB 
123 HbA1C level more than 47.5 mmol/ml was 
a significant relationship with sputum 
conversion for more than two months, RR 
6.3 (1.9-39.6) (p<0.05) 
Kulsum et al., 2017 14 A prospective cohort study 
of new cases of TB 
84 After two months of intensive phase failures 
in TB-DM patients, the proportion of 
sputum conversion was 43.04% vs. 22.75% 
(p<0.05). HbA1C level is one of the risk  
factors for conversion failure (p=0.014) 
Oceguera et al., 2015 
15 
A retrospective study of TB 
cases during five years 
88 Time to sputum conversion in patients 
TB+DM with HbA1C more than and less 
than 6.5% was 68.9 days vs. 110.0 days, 
respectively (p>0.05). Time to culture 
conversion  in MDR-TB patients with DM 
was 93.5 days vs. 75.9 days in MDR-TB 
patients without DM (p>0.05) 
Yoon et al., 2017 16 A prospective cohort study 
of pulmonary TB 
661 TB patients with DM who had uncontrolled 
diabetes (HbA1c > 7%) were significantly  
associated with the positive culture after two 
months of treatment, treatment failure, and 
death (p<0.05). Patients with controlled DM 
has a favorable outcome treatment similar to 
the non-DM group. 
Chiang et al., 2015 17 A prospective cohort study 
of pulmonary TB 
1.473 Diabetic patients with HbA1c > 9% were 
significantly more likely to be smear-
positive than those without diabetes.  
DISCUSSION 
The Correlation Between DM and Infection 
(TB) 
   Pulmonary TB and DM are chronic and 
related diseases. Pulmonary TB will not 
recover sufficiently in uncontrolled diabetes. 
Pulmonary TB patients with DM have 
different characteristics, so they often 
undiagnosed, and therapy is challenging due 
to the interaction between TB drugs and oral 
antidiabetics. Factors associated with 
pulmonary TB in T2DM were close contact 
with other TB patients, the length of suffering 
from DM, and HbA1c levels. Wijayanto et al. 
reported that patients who have diabetes for a 
long time have a significant association with 
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TB infection in DM patients (OR 23.13; CI 
95% 4.6-11), but it did not examine the 
relationships between the length of suffering 
from DM sputum conversion.12 Measurement 
of HbA1c levels was more accurate to predict 
the prognosis of TB in TB-DM patients 
compared to blood glucose level.  HbA1c 
level described blood glucose levels during 
the past 2-3 months and was not influenced 
by oral antidiabetic medication or food taken 
soon before the examination. 
 Several studies have reported that high-
level HbA1c was associated with increased 
TB infection risk, but many of them did not 
analyze the association with sputum 
conversion. A systematic review of the 
observational study by Jeon et al. reported 
that low blood sugar control or uncontrolled 
HbA1c significantly increases the risk of 
infection TB with a hazard ratio of 1.39 per 
unit of increase in HbA1c levels (CI 95% 
1.18-1.63).18 A study by Bartelink et al. stated 
that there was no significant difference in 
average levels of HbA1c in T2DM patients 
with and without infection. In contrast, 
patients who had an infection during the 
follow-up period showed a higher level of 
HbA1c compared to patients without 
infection. Several studies have measured at 
once HbA1c levels on specifically selected 
infections.19 A poor glycemic control 
characterized by a high level of HbA1c was 
associated with systemic infections,20,21 
pneumonia requiring hospitalization,22 
tuberculosis (TB), 23 urinary tract 
infections,24 and woman reproductive 
infection.25 A study by Critchley et al. stated 
that poor glycemic control in diabetic patients 
was significantly associated with severe 
infections such as bone and joint infection 
(46%), tuberculosis (24%), and sepsis 
(21%).26  
 
Association Uncontrolled HbA1c With 
Therapeutic Outcome of Antituberculosis 
Treatment 
 Several studies have reported 
uncontrolled diabetes, characterized by 
HbA1c level > 7% among T2DM with TB. A 
study by Wahiduddin et al. stated that the 
HbA1c level in DM patients with pulmonary 
TB was higher (11.2%) than those without 
pulmonary TB (9.3%). This study was also 
reported that less than T2DM with TB 
achieving HbA1c level <7%.27 Several 
studies reported a high proportion of 
uncontrolled diabetes with HbA1c levels of 
more than 7% in T2DM with TB. Boyilla N 
et al. reported that in T2DM with pulmonary 
TB, the proportion of HbA1c > 9% was 
58.33%, while HbA1c <7% was 15.28%.28 
Ahmed M et al. found most of the T2DM 
patients with pulmonary TB, 58.6% had 
uncontrolled HbA1c levels (> 6.5%).29 It 
indicated that the glycemic control in T2DM 
with TB was poor. 
 Based on table 1, all of the studies were 
observational with a cohort design. Studies 
reported that uncontrolled diabetes with 
HbA1c > 7% was significantly associated 
with positive smear sputum or positive 
culture at a second month or the end of the 
intensive phase. One hypothesis showed that 
T2DM with TB impaired the antituberculosis 
treatment outcome. This condition is due to 
the immune dysregulation function. Several 
studies evaluating immune function in T2DM 
patients reported a dysregulation immunity, 
both innate and adaptive immunity. The 
dysregulation immunity was characterized by 
decreased interleukin 1 (IL-1) and IL-6 
secretion by neutrophil cells and monocytes. 
It can decrease mobilization, chemotaxis, 
phagocytosis of phagocytic cells. It was also 
decreased T cell response and impaired 
humoral immunity.30,31   
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 Natural killer (NK) cell functions and 
their relationship with glycemic control level 
have not been widely studied.32 NK cells are 
very important against viral and bacterial 
infections as well as control cancer growth. 
Meanwhile, T2DM patients with poor 
glycemic control have a higher risk of viral or 
bacterial infections and cancer. Previous 
studies reported a reduction activity of NK 
cells in T2DM,33,34 but studies relating 
glycemic control and NK cells research 
activity were very rare. A study by Berrou et 
al. reported that a decreased NK cell activity 
in T2DM patients was negatively correlated 
with HbA1c levels.33 Several mechanisms are 
thought to explain these findings: 
hyperglycemia against the expression of 
glucose transporter (GLUT1, GLUT3, and 
GLUT4).35 
 Glucose is an important energy source 
for metabolism and cell activity, including 
immune cells such as leukocytes and NK 
cells. Impaired transporter expression of 
glucose will cause NK cells to lack energy 
and unable to activate their function. Besides, 
hyperglycemia in T2DM patients causes 
stress on the endoplasmic reticulum and leads 
to low expression of NK cell activation 
receptors such as NKG2D 33. Furthermore, 
poor glycemic control in DM patients can 
disrupt NK cell activity, explaining DM 
patients' increased susceptibility against viral 
or bacterial infections and cancer. However, 
Ristanti et al. reported that the glycemic 
control did not significantly correlate with 
NK cell activity in T2DM.36 
 A study by Kulsum et al. reported that the 
median level of HbA1c in the non-conversion 
group was significantly 10% higher than 
HbA1c levels in the conversion group (8.5%). 
A high level of HbA1c was also associated 
with increased failure of sputum conversion 
after correcting in albumin and acid-fast 
bacilli (AFB) positive level before 
antituberculosis treatment (p = 0.018, aOR 
1.298, CI 95% 1.047-1.610).14 The study by 
Jiyani et al. was also reported that 50% of 
patients who had sputum smear positivity 
before therapy (3+) were TB-DM patients 
with HbA1c levels > 8%. Still, this study did 
not analyze the relationship between HbA1c 
levels and sputum conversion.37  
In experimental animal models with 
chronic hyperglycemic, inflammatory cells 
and mediators are similar.  It is even higher 
than that in euglycemic animals. However, 
there is a decrease in the cellular immune 
response. This was also characterized by 
inadequate binding and ingesting of the 
peripheral blood monocytes (PBM) with M. 
tuberculosis in T2DM patients.38 A proposed 
mechanism for the disability of macrophages 
to respond to M. tuberculosis in diabetic 
patients may be due to the reduction in nitric 
oxide production and H2O2 in the 
macrophages,39 processes in which PARP1 is 
actively involved.40,41 Therefore, diabetic 
patients, especially with HbA1c levels above 
8%, were associated with a longer time to 
smear or culture conversion and a higher 
incidence of treatment failure 
 
Interaction of Diabetes With 
Antituberculosis Drugs 
 
It has been proposed that there were 
significant interactions between 
antituberculosis drugs and oral antidiabetic. 
And it was also worsening in the clinical 
outcome of TB patients with DM. Several 
studies have examined the effect of diabetes 
mellitus on the PK-PD of antituberculosis 
drugs. The results were contradictive or 
inconsistent. Several studies on TB patients 
with DM showed that the concentration of 
antituberculosis drugs was lower.42-44 While 
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Antituberculosis medications concentration 
on TB-DM patient's, especially rifampicin, 
was lower than in TB without DM. It was 
because of the alteration of drug absorption, 
distribution, and elimination (metabolism and 
excretion) in TB patients with DM. A study 
by Nijland et al. stated that the serum 
concentration of rifampicin in TB patients 
with DM was 53% lower than in TB patients 
without DM. A low concentration of 
antituberculosis drugs was predicted to cause 
poor clinical outcomes, and the risk of 
treatment failure was nine folds higher than 
that of high concentration.42  
A study by Kusibawati et al. reported 
interaction between rifampicin and 
sulphonylurea, glipizid.  It was found that 
rifampicin can stimulate the formation of 
cytochrome P-450 isoenzyme CYP2C9 to 
metabolize glizipid.  Rifampicin accelerates 
the elimination of glipizid and lowers the 
glipizid concentration in blood circulation. 
Rifampicin is also proven to induce potent 
hepatic microsomal enzymes. Rifampicin 
also plays a role with another drug 
metabolism in the mixed-function oxidase 
(MFO) system. This system acts in a first-
phase oxidase reaction in drug metabolism.47  
An optimal therapy strategy for TB 
patients with DM has not been established. 
There is no best scientific evidence that 
supports the differences in regimen, 
especially antituberculosis drugs, between 
TB patients with and without DM. For TB 
patients with DM, the therapy and duration of 
antituberculosis medications are similar to 
TB patients without DM. In the intensive 
phase, four regimens of antituberculosis 
drugs (rifampicin, isoniazid, ethambutol, and 
pyrazinamide) are given daily for two 
months. In the advanced phase, rifampicin 
and isoniazid are administered daily or 
intermittently for four months, when blood 
sugar is well controlled. However, when 
blood sugar is poorly controlled, it will be 
extended to seven until nine months.   
A systematic review reported that 
intermittent treatment in the advanced phase 
has a higher risk of treatment failure, relapse, 
and drug resistance than daily dose therapy. 
In 2017, WHO has no longer recommended 
intermittent treatment in the advanced phase. 
Interestingly, a study by Siane et al. stated 
that there were no differences between smear 
conversion and success rate in the advanced 
phase in TB patients with DM between daily 
and intermittent treatment.48 However, this 
study has some limitations. This study was a 
retrospective study from the medical record 
of TB-DM patients. The number of patients 
was relatively small, so it can't directly be 
applied to the general population.  
A recent study by Alfarisi et al. reported 
that DM influenced pyrazinamide's 
pharmacokinetics. It also increases maximum 
concentration (Cmax) above the therapeutic 
concentration. A high level of Cmax of 
pyrazinamide was significantly associated 
with treatment failure, relapse, and death. The 
therapeutic concentration against 
Mycobacterium tuberculosis of rifampicin, 
isoniazid, and pyrazinamide is 8 mcg/ml, 3 
mcg/ml, and 35 mcg/ml, respectively. Among 
the antituberculosis drugs, only pyrazinamide 
has a significantly lower TB concentration 
with DM than those without DM. In addition, 
an increase in HbA1c levels was followed by 
a decrease in pyrazinamide concentration.  
TB patients with DM, the concentration of 
rifampicin and isoniazid, were positively 
associated with time to culture conversion, 
but not with pyrazinamide concentration.49  
In TB patients with DM, the rifampicin 
concentration was significantly reduced 
compared to TB patients without DM. 
 Interestingly, data from several studies 
were contradictory. Some studies reported a 
slower absorption and reduced rifampicin 
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concentration.43  While others showed no 
significant effect of DM on the 
pharmacokinetics profile of rifampicin.50 It 
was because of the differences in 
demographic patients, the severity of DM, the 
dose of antituberculosis drugs, and study 
design. In the continuous phase, rifampicin 
with a dose of 450 mg-600 mg was 
administered to TB patients thrice weekly or 
well known as intermittent dose and has been 
associated with worsened clinical outcome. 
Thus, a higher and daily dose of rifampicin is 
needed to achieve a targeted clinical outcome.   
 A low concentration of isoniazid in TB 
patients with DM may be related to DM-
induced intestinal motility changes. Due to 
isoniazid metabolization through N-
acetyltransferase 2 (NAT2), the rapid 
acetylators population reduces the plasma 
level of isoniazid 51. Whether patients with 
DM should be administered a higher dose of 
antituberculosis was not clearly stated. An 
adequate dose of isoniazid (which reduces 
tuberculosis bacterial quickly) and rifampicin 
(which is the key sterilizing drugs) as the 
main anti-TB drugs in six months of therapy, 
including intensive and continuous phase, 
was needed to achieve sputum or culture 
conversion.  
 Insulin, oral hypoglycemic agent, and the 
combination between insulin and 
hypoglycemic agent improved the HbA1c 
level in T2DM with TB was observed by 
Wahiduddin et al. In T2DM with TB patients 
who uses insulin, oral hypoglycemic agent, 
and combination, HbA1c level was 10.29%, 
12.23%, and 11.12% respectively. It was 
much higher than those without TB.27  
However, this study did not report the type 
and dose of insulin and oral hypoglycemic 
agent that alter the HbA1c level, so it must 
carefully interpret in clinical settings.  
 Conversely, a hypoglycemic event 
resulting from the interaction between 
isoniazid and glimepiride was reported by 
Boglou et al. Primarily, glimepiride is 
metabolized in the liver via the cytochrome 
P450 isoenzyme CYP2C9 to its active 
metabolite and then metabolized to its 
dehydrogenated inactive metabolite. The 
inhibition process of cytochrome leads to the 
accumulation of parent drug glimepiride, 
resulting in hypoglycemia. Isoniazid, one of 
the antituberculosis drugs, is a strong 
inhibitor of CYP2C9 and other cytochrome 
P450 isoenzymes such as CYP2C19 and 
CYP2E1. Therefore, co-administration with 
glimepiride could increase its concentration 
in blood circulation.52 Thus, administration of 
isoniazid in DM patients, especially with 
concurrent acute illness who receive 




 From this review, it can be concluded 
that uncontrolled diabetes, which is 
characterized by a high level of HbA1c > 6.5-
7.0%, was significantly associated with delay 
of sputum smear conversion or culture 
conversion more than two months in TB 
patients with DM.  Clinicians and 
pharmacists should collaborate to increase 
attention to HbA1c level or glucose level in 
TB patients with DM to achieve a better 
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